The abstract is read at the publisher; the summary is JClub's.
Covalent inhibitor potency is better characterized by time-dependent binding kinetics, using k inact and K I plus residence time τ, rather than static IC 50 alone.
- Why it matters: Equilibrium metrics like IC 50 miss how fluctuating drug and target levels and slow complex formation/breakdown shape exposure, especially for irreversible covalent drugs.
- What they did: The review summarizes practical assays—progress-curve kinetics, multi-timepoint IC 50 fitting (EPIC), mass spectrometry adduct confirmation, label-free SPR/NMR validation, and washout/jump-dilution—to estimate k inact, K I, and τ.
- The result: It links microscopic rates to pharmacology via protein turnover, target vulnerability, and pharmacokinetics, and proposes reporting standards (IC 50 with incubation time; k inact /K I ; τ; turnover-driven occupancy) to guide kinetics-first optimization.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.